New drug combo targets genetic weakness in tough cancers
Disease control
Recruiting now
This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC